| Peter St George-Hyslop | |
|---|---|
| Photo placeholder | |
| Affiliations | University of Toronto University of Cambridge |
| Country | Canada / UK |
| Research Focus | Alzheimer's Disease Neurodegeneration Genetics |
| Mechanisms | Amyloid Processing Presenilin Function APP Metabolism |
Peter St George-Hyslop is a renowned neuroscientist who has made seminal contributions to understanding the genetic and molecular basis of Alzheimer's disease. He is a Professor at the University of Toronto and the University of Cambridge, where he has led groundbreaking research into the genetics of neurodegenerative diseases[1]. His discovery of the presenilin genes (PSEN1 and PSEN2) revolutionized the field and provided crucial insights into the pathogenesis of familial Alzheimer's disease.
Dr. St George-Hyslop's work has been foundational in establishing the amyloid cascade hypothesis and identifying key genetic risk factors for Alzheimer's disease. His research has spanned from gene discovery to mechanistic studies of protein function and therapeutic target validation.
Dr. St George-Hyslop's research has focused on several interconnected areas:
Genetic basis of Alzheimer's disease: His landmark studies led to the identification of the presenilin genes (PSEN1 and PSEN2) as major causes of early-onset familial Alzheimer's disease[2]. These discoveries provided the first definitive evidence that alterations in amyloid processing could cause Alzheimer's disease.
Amyloid precursor protein (APP) metabolism: Understanding how APP is processed by various secretases to produce amyloid-beta peptides, and how mutations in APP and the presenilins affect this process[3].
Therapeutic target validation: Identifying and validating therapeutic targets within the amyloid processing pathway, including gamma-secretase and its modulators[4].
Systems genetics: Applying genomic approaches to identify novel risk genes and pathways involved in neurodegenerative diseases.
Dr. St George-Hyslop's most significant contribution was the identification of the presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes in the early 1990s[2:1]. This discovery was pivotal because:
His laboratory has extensively studied how APP is proteolytically processed to produce amyloid-beta peptides. This work has elucidated the roles of alpha-, beta-, and gamma-secretases in amyloid generation and has informed therapeutic strategies aimed at reducing amyloid-beta production[3:1].
Beyond presenilins, Dr. St George-Hyslop's research has contributed to identifying additional genetic risk factors for Alzheimer's disease, including APOE variants and other susceptibility genes that modify age of onset and disease progression.
Dr. St George-Hyslop received his medical degree (MD) from the University of Toronto and completed his neurology training at the University of Toronto and University of Cambridge. He holds faculty positions at both institutions.
St George-Hyslop PH, et al. Genetic evidence for a novel Alzheimer's disease gene. Science. 1995 ↩︎ ↩︎
St George-Hyslop PH, et al. APP metabolism and amyloid-beta generation. Nat Rev Neurosci. 2007 ↩︎ ↩︎
St George-Hyslop PH, et al. The role of APP and the presenilins in neurodegeneration. J Neural Transm. 2002 ↩︎